Plain-English translation of NCT04990102 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether , a chemotherapy medication given by IV infusion, can help keep acute myeloid leukemia (AML) in remission long-term. You would receive this treatment over 6 cycles after your cancer has already responded to initial treatment. The goal is to prevent your cancer from coming back.
After initial treatment for AML, many patients face the risk of relapse—the cancer returning. This medication is being studied to see if it can reduce that risk in patients who are not eligible for bone marrow transplants, which is the standard approach for preventing relapse in some patients.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the medication either twice per cycle (on days 1 and 3) or once per cycle (on day 1 only), depending on which dose the study determines is safest and most effective. Treatment continues for 6 cycles, with each cycle lasting 28 days. You would need to visit the clinic regularly for infusions and to have your blood counts and organ function monitored.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States